MAIDNCT07885462
Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills
StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 4 words
- Start date pushed from Oct 2026 to Nov 2026
- Secondary endpoints: details revised at 1 of 4 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from baseline in peak coronary flow reserve (CFRmax) of the left anterior descending artery
Timeframe: Baseline, 6 months, and 12 months
Secondary (4)
Change from baseline in mean coronary flow reserve (CFRmean) of the left anterior descending artery
Change from baseline in Seattle Angina Questionnaire (SAQ) score
Change from baseline in CCS angina class
Incidence of major adverse cardiovascular events (MACE) within 12 months
Arms and interventions
Conventional treatment + Compound Danshen Dripping Pills 540 mgExperimental
Participants receive conventional treatment plus Compound Danshen Dripping Pills (CDDP), 20 pills (540 mg) orally three times daily for 12 months.
Conventional treatment + matching placeboPlacebo comparator
Participants receive conventional treatment plus placebo pills matching CDDP in appearance, 20 pills orally three times daily for 12 months.
Drugs: Compound Danshen Dripping Pills, Placebo
Sites
1 site in 1 country
- Qilu Hospital of Shandong UniversityJinan, Shandong, China